Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria, Eur J Clin Invest, vol.37, pp.435-53, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00152499
Diagnostic criteria and classification of mastocytosis: a consensus proposal, Leuk Res, vol.25, pp.603-628, 2001. ,
Phenotypic and genotypic characteristics of mastocytosis according to the age of onset, PLoS ONE, vol.3, p.1906, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00282484
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations, J Invest Dermatol, vol.130, pp.804-819, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00437282
Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis, Leuk Res, vol.25, pp.563-70, 2001. ,
Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish network on mastocytosis (REMA), Cytometry B Clin Cytom, vol.58, pp.1-8, 2004. ,
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes, J Allergy Clin Immunol, vol.125, pp.1-726, 2010. ,
Blood CD34-c-Kit? cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor, Blood, vol.118, pp.5246-5255, 2011. ,
Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant, Mol Cancer Ther, vol.1, pp.1115-1139, 2002. ,
The aberrant localization of oncogenic Kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment, Mol Cancer Res, vol.7, pp.1525-1558, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00421163
Mastocytosis (mast cell disease). World Health Organization (WHO) Classification of Tumours, vol.1, pp.291-302, 2001. ,
Indolent Systemic Mast Cell Disease in Adults: Immunophenotypic Characterization of Bone Marrow Mast Cells and its Diagnostic Implications, Blood, vol.98, pp.2731-2737, 1998. ,
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis, Clin Cancer Res, vol.14, pp.3906-3921, 2008. ,
Chemotherapy and dasatinib induce longterm hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT, Leuk Res, vol.816, pp.735-776, 2009. ,
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy, Blood, vol.109, pp.2303-2312, 2007. ,
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation, Blood, vol.106, pp.2865-70, 2005. ,
KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors, Clin Cancer Res, vol.14, pp.2285-94, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00283136
Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes, Mol Cell, vol.36, pp.326-365, 2009. ,
The constitutive activity of the ALK mutated at positions F1174 or R 1275 Impairs receptor trafficking, Oncogene, vol.30, pp.2017-2042, 2011. ,